Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cellectis Success With Off-The-Shelf CAR-T Threatens Kite, Juno, Novartis

This article was originally published in Scrip

Executive Summary

An unexpected breakthrough announced by Cellectis for its experimental off-the-shelf CAR-T therapy has raised the possibility that much-hyped therapies using a patient's own cells, under development at Kite, Juno and Novartis, may become commercially obsolete before they even reach the market.

You may also be interested in...



Cellectis Files IND For Talen-Edited 'Off-The-Shelf' CAR-T Candidate

Cellectis has filed an IND for US testing of its TALEN-edited CAR-T immune-oncology therapy UCART123. Servier has already begun clinical testing with Cellectis' lead program, UCART19, in Europe. The product is licensed to Pfizer in the US.

Deal Watch: Roche Aborts But Regeneron, Amgen and Pfizer Sign Up

Deal activity over the past seven days sees Roche knock back Inovio a second time, Regeneron plan for its future via an alliance with Adicet Bio, Amgen supplement its preclinical pipeline with a candidate from Advaxis, and Pfizer shore up its gene therapy ambitions with an acquisition.

Kite And Juno Threatened By Cellectis' Off-The-Shelf CAR-T Success

An unexpected breakthrough announced by Cellectis for its experimental off-the-shelf CAR-T therapy has raised the possibility that much-hyped therapies using a patient's own cells, under development at Kite Pharma and Juno Therapeutics may become commercially obsolete before they even reach the market.

Topics

Related Companies

UsernamePublicRestriction

Register

SC030289

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel